Summary
In the last decade neurohormone replacement therapy with levodopa has revolutionised the treatment of Parkinson’s disease. At the same time the use of amantadine and dopamine-like ergot drugs has developed, although there is still a place for anticholinergic drugs, now in use for a century. These advances have resulted in the availability of many different drugs to treat Parkinsonism with different pharmacological actions. It is now usually possible to control disability, at least in the initial stages of disease, although sometimes at the expense of frequent and disabling side effects. In most cases these result from the widespread distribution of cholinergic and dopaminergic systems inside and outside the brain and the non-selective action of therapeutic agents on these different systems. Despite the recent division of dopamine receptors into D1 and D2 classes, no selective dopamine-like antiparkinsonian drugs are known.
The practical treatment of Parkinsonism depends on accurate knowledge of the side effects as well as therapeutic effects of many different drugs, and requires titration of individually determined dosages in different patients to achieve the optimum response. This is usually determined by dose-limiting side effects as well as by improvement. The possibility that the eventual development of response fluctuation and failure may result from the sustained use of large doses of dopamine-like drugs must be considered, and it is probably wise at present to give low rather than high doses of these agents. No presently available treatment appears to influence the natural progression of Parkinsonism.
Similar content being viewed by others
References
Barbeau, A.: L-dopa therapy in Parkinson’s disease: a critical review of nine years’ experience. Journal of the Canadian Medical Association 101: 59–68 (1969).
Bédard, P; Parkes, J.D. and Marsden, CD.: Effect of new dopamine-blocking agent (oxiperomide) on drug-induced dyskinesias in Parkinson’s disease and spontaneous dyskinesias. British Medical Journal 1: 954–956 (1978).
Bennett, W.M.; Singer, I. and Coggins, C.H.: Guide to drug usage in adult patients with impaired renal function. Journal of the American Medical Association 223: 991–997 (1973).
Besser, G.M.; Thorner, MO.; Wass, J.A.H.; Doniach, I.; Canti, G.; Curling, M.; Grudziniskas, J.G. and Setchell, M.E.: Absence of uterine neoplasms in patients on bromocriptine. British Medical Journal 2: 868 (1977).
Birkmayer, W.; Riederer, P.; Ambrozi, L. and Youdim, M.B.H.: Implications of combined treatment with Madopar and 1-deprenil in Parkinson’s disease. Lancet 1: 439–443 (1977).
Calne, D.B.; Williams, C; Neophytides, A.; Plotkin, C; Nutt, J.G. and Teychenne, P.F.: Long-term treatment of parkinsonism with bromocriptine. Lancet 1: 735–738 (1978).
Cant, J.S.: Iatrogenic eye disease. Practitioner 202: 787–795 (1969).
Carlsson, A.; Kehr, W. and Lindqvist, M.: The role of intraneuronal amine levels in the feedback control of dopamine, noradrenaline and 5-hydroxy-tryptamine synthesis in rat brain. Journal of Neural Transmission 39: 1–19 (1976).
Brogden, R.N.; Speight, T.M. and Avery, G.S.: Levodopa, A review of its pharmacological properties and therapeutic uses with particular reference to parkinsonism. Drugs 2: 262–400 (1971).
Clark, B.J.; Scholtysik, G. and Flückiger, E.: Cardiovascular actions of bromocriptine. Acta Endocrinologia (Suppl.) 216: 78–81 (1978).
Costall, B. and Naylor, R.J.: Neuroleptic antagonism of dyskinetic phenomena. European Journal of Pharmacology 33: 301–312 (1975).
Davis, P.L. and Stewart, W.B.: The use of benzedrine sulfate in post-encephalitic parkinsonism. Journal of the American Medical Association 110: 1890–1892 (1938).
Dunner, D.L.; Brodie, H.K.H. and Goodwin, F.K.: Plasma DOPA response to levodopa administration in man: Effects of a peripheral decarboxylase inhibitor. Clinical Pharmacology and Therapeutics 12: 212–217 (1971).
Duvoisin, R.C.: Hypotension caused by levodopa. British Medical Journal 3: 47 (1970).
Duvoisin, R.C. and Katz, R.: Reversal of central anticholinergic syndrome in man by physostigmine. Journal of the American Medical Association 206: 1963–1965 (1968).
Editorial. Mental changes in Parkinsonism. British Medical Journal 2: 1–2 (1974).
El-Yousef, M.K.; Janowsky, D.S.; David, J.M. and Sekerke, H.J. Reversal of benztropine toxicity by physostigmine. Journal of the American Medical Association 220: 125 (1972).
Fahn, S.; Craddock, G. and Kumin, G.: Acute toxic psychosis from suicidal overdosage of amantadine. Archives of Neurology 25: 45–48 (1971).
Friedman, Z. and Neumann, E.: Benzhexol-induced blindness in Parkinson’s disease. British Medical Journal 1: 605 (1972).
Glover, V.; Sandier, M.; Owen, F. and Riley, G.J.: Dopamine is a monoamine oxidase B substrate in man. Nature 265: 80–81 (1977).
Godwin-Austen, R.B.; Frears, C.C.; Bergmann, S.; Parkes, J.D. and Knill-Jones, R.P.: Combined treatment of parkinsonism with l-dopa and amantadine. Lancet 2: 383–385 (1970).
Griffith, R.W.; Turkalj, I. and Braun, P.: Outcome of pregnancy in mothers given bromocriptine. British Journal of Clinical Pharmacology 5: 227–231 (1978).
Hacohen, H. and Gurtner, B.: Klinische prufung des therapieseffektes von Amantadin-HCI bei morbus parkinson. Schweizerische Medizinische Wochenschrift 102: 583–586 (1972).
Harper, R.W. and Knothe, B.: Coloured Lilliputian hallucinations with amantadine. Medical Journal of Australia 1: 444–445 (1973).
Klawans, H.L. and Weiner, W.J.: Attempted use of haloperidol in the treatment of l-dopa induced dyskinesias. Journal of Neurology, Neurosurgery and Psychiatry 37: 427–430 (1974).
Lees, A.J.; Shaw, K.M.; Kohout, L.J.; Stern, G.M.; Elsworth, J.D.; Sandler, M. and Youdim, M.B.H.: Deprenyl in Parkinson’s disease. Lancet 2: 791–796 (1977).
Lhermitte, F.; Agid, Y.; Signoret, J-L. and Studier, J-M.: Les dyskinesies de ‘debut et fin de dose’ provoquees par la l-dopa. Revue Neurologique 133: 297–308 (1977).
Morgan, J.P.; Bianchine, J.R.; Spiegel, H.E.; Rivera-Calimlim, L. and Hersey, R.M.: Metabolism of levodopa in patients with Parkinson’s disease. Radioactive and fluorometric assays. Archives of Neurology 25: 39–44 (1971).
Muenter, M.D.: Double-blind, placebo controlled study of levodopa therapy in Parkinson’s disease. Neurology 20 (Suppl.): 673 (1970).
Parkes, J.D.: Side effects of bromocriptine. New England Journal of Medicine 302: 749–750 (1980).
Pearce, J.: Mechanism of action of amantadine. British Medical Journal 3: 529 (1971).
Piper, D.W. and Heap, T.R.: Medical management of peptic ulcer with reference to anti-ulcer agents in other gastro-intestinal diseases. Drugs 3: 366–403 (1972).
Price, P.; Parkes, J.D. and Marsden, CD.: Tiapride in Parkinson’s disease. Lancet 2: 1106 (1978).
Rao, N.S. and Pearce, J.: Amantadine in parkinsonism. An extended prospective trial. Practitioner 206: 241–245 (1971).
Scherf, D.: Atropine in acute myocardial infarctions. American Heart Journal 86: 284 (1973).
Schwab, R.S.; England, A.C.; Poskanzer, D.C. and Young, R.R.: American Medical Association 208: 1168 (1969).
Shealy, C.N.; Weeth, J.B. and Mercier, D.: Livedo reticularis in patients with parkinsonism receiving amantadine. Journal of the American Medical Association 212: 1522–1523 (1970).
Smith, S.E.: Mydriatic drugs for routine fundal infection. Lancet 2: 837–839 (1971).
Tarsy, D.; Parkes, J.D. and Marsden, CD.: Metoclopramide and pimozide in Parkinson’s disease and levodopa-induced dyskinesias. Journal of Neurology, Neurosurgery and Psychiatry 38: 331–335 (1975).
Teychenne, P.F.: Hepatocellular injury with distinctive metochondrial changes induced by lergotrile mesylate: A dopaminergic ergot derivative. Gastroenterology 76: 575–583 (1979).
Tolosa, E.S.: Paradoxical suppression of chorea by apomorphine. Journal of the American Medical Association 229: 1579–1580 (1974).
Vitetta, M.: Effetti dell’amantadina sullo stato di viglanza nelle psicosindromi cerebrali diffuse vasculopatiche. Minerva Medica 62: 3984–3986 (1971).
Weiner, W.J.; Kramer, J.; Nausieda, P.A. and Klawans, H.L.: Paradoxical response to dopaminergic agents in Parkinsonism. Archives of Neurology 35: 453–455 (1978).
Winer, J.A. and Bahn, S.: Loss of teeth with antidepressant drug therapy. Archives of General Psychiatry 16: 239–240 (1967).
Wood, B. and Haq, E.U.: An unusual case of atropine poisoning. British Journal of Clinical Practice 25: 469–470 (1971).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Parkes, J.D. Adverse Effects of Antiparkinsonian Drugs. Drugs 21, 341–353 (1981). https://doi.org/10.2165/00003495-198121050-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198121050-00002